Arch Biopartners (TSXV:ARCH) Total Liabilities : C$6.35 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Total Liabilities?

Arch Biopartners's Total Liabilities for the quarter that ended in Dec. 2023 was C$6.35 Mil.

Arch Biopartners's quarterly Total Liabilities declined from Jun. 2023 (C$7.17 Mil) to Sep. 2023 (C$6.68 Mil) and declined from Sep. 2023 (C$6.68 Mil) to Dec. 2023 (C$6.35 Mil).

Arch Biopartners's annual Total Liabilities declined from Sep. 2021 (C$6.55 Mil) to Sep. 2022 (C$5.09 Mil) but then increased from Sep. 2022 (C$5.09 Mil) to Sep. 2023 (C$6.68 Mil).

Arch Biopartners Total Liabilities Historical Data

The historical data trend for Arch Biopartners's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Total Liabilities Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

3.47

4.61

6.55

5.09

6.68

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															5.19	9.12	7.17	6.68	6.35

Arch Biopartners Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Arch Biopartners's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.977	+	(0.704	+	-2.2204460492503E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	6.68

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	1.171	-	-5.51
	=	6.68

Arch Biopartners's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.85	+	(0.5	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	6.35

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	0.636	-	-5.713
	=	6.35

Arch Biopartners Total Liabilities Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.